UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 


 

Date of Report (Date of earliest event reported):  May 5, 2015

 

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

1-11083

 

04-2695240

(State or other

 

(Commission

 

(IRS employer

jurisdiction of

 

file number)

 

identification no.)

incorporation)

 

 

 

 

 

300 Boston Scientific Way, Marlborough, Massachusetts

 

01752-1234

(Address of principal executive offices)

 

(Zip code)

 

Registrant’s telephone number, including area code: (508) 683-4000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

ITEM 5.07.          SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

(a)           Boston Scientific Corporation (the “Company”) held its 2015 Annual Meeting of Stockholders (the “Annual Meeting”) on May 5, 2015 at its Corporate Headquarters located in Marlborough, Massachusetts.

 

(b)           The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

 

(1)                     All eleven director nominees were elected to the Company’s Board of Directors for a one-year term to hold office until the Company’s 2016 Annual Meeting of Stockholders and until their successors have been elected and qualified.

 

Nominee

 

For

 

Withheld

 

Broker Non-Votes

Nelda J. Connors

 

1,100,607,449

 

 

17,045,045

 

 

56,352,573

 

Charles J. Dockendorff

 

1,106,857,157

 

 

10,795,337

 

 

56,352,573

 

Kristina M. Johnson

 

1,101,047,615

 

 

16,604,879

 

 

56,352,573

 

Edward J. Ludwig

 

1,102,566,527

 

 

15,085,967

 

 

56,352,573

 

Stephen P. MacMillan

 

1,097,304,916

 

 

20,347,578

 

 

56,352,573

 

Michael F. Mahoney

 

1,103,435,990

 

 

14,216,504

 

 

56,352,573

 

Ernest Mario

 

716,615,095

 

 

401,037,399

 

 

56,352,573

 

N.J. Nicholas, Jr.

 

971,605,297

 

 

146,047,197

 

 

56,352,573

 

Pete M. Nicholas

 

1,095,195,859

 

 

22,456,635

 

 

56,352,573

 

David J. Roux

 

1,102,085,411

 

 

15,567,083

 

 

56,352,573

 

John E. Sununu

 

1,100,206,409

 

 

17,446,085

 

 

56,352,573

 

 

(2)                     The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting (the “Proxy Statement”) was approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

1,099,762,641

 

15,075,270

 

2,814,583

 

56,352,573

 

(3)                     The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2015 fiscal year was ratified.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

1,162,172,501

 

10,444,359

 

1,388,207

 

N/A

 

(4)                     The stockholder proposal regarding accountability in animal use as described in the Proxy Statement was not approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

31,831,102

 

836,036,432

 

249,784,960

 

56,352,573

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BOSTON SCIENTIFIC CORPORATION

 

 

 

 

Date:      May 6, 2015

By:

/s/ Vance R. Brown

 

Vance R. Brown

 

Vice President and Chief Corporate Counsel

 

3